2025
Target Trial Emulation of Severe Acute Respiratory Syndrome Coronavirus 2 Infection Versus No Infection and Risk of Post–Coronavirus Disease 2019 Conditions in the Omicron Variant Versus Prior Eras
Ioannou G, Berry K, Rajeevan N, Li Y, Yan L, Huang Y, Bui D, Hynes D, Rowneki M, Hickok A, Niederhausen M, Shahoumian T, Bohnert A, Boyko E, Korpak A, Fox A, Baraff A, Iwashyna T, Maciejewski M, Smith V, Berkowitz T, Pura J, Hebert P, Wong E, O’Hare A, Osborne T, Viglianti E, Aslan M, Bajema K. Target Trial Emulation of Severe Acute Respiratory Syndrome Coronavirus 2 Infection Versus No Infection and Risk of Post–Coronavirus Disease 2019 Conditions in the Omicron Variant Versus Prior Eras. Clinical Infectious Diseases 2025, ciaf087. PMID: 40208261, DOI: 10.1093/cid/ciaf087.Peer-Reviewed Original ResearchPost-COVID-19 conditionCumulative incidence of deathVeterans Health AdministrationMatched index dateCumulative incidence differenceExcess burdenCumulative incidenceBurden of mortalityHypothetical target trialIncidence of deathDeath up to 1 yearTarget trial emulationAll-cause mortalityHealth recordsHealth AdministrationTrial emulationIncidence differencesIndex dateUninfected participantsPost-coronavirus diseaseVeteransUnvaccinated personsTarget trialsOmicron eraVaccination statusEffectiveness of the 2023-to-2024 XBB.1.5 COVID-19 Vaccines Over Long-Term Follow-up : A Target Trial Emulation.
Ioannou G, Berry K, Rajeevan N, Li Y, Yan L, Huang Y, Lin H, Bui D, Hynes D, Rowneki M, Bohnert A, Boyko E, Iwashyna T, Maciejewski M, Smith V, Berkowitz T, O'Hare A, Viglianti E, Aslan M, Bajema K. Effectiveness of the 2023-to-2024 XBB.1.5 COVID-19 Vaccines Over Long-Term Follow-up : A Target Trial Emulation. Annals Of Internal Medicine 2025, 178: 348-359. PMID: 39903865, DOI: 10.7326/annals-24-01015.Peer-Reviewed Original ResearchConceptsU.S. Department of Veterans AffairsDepartment of Veterans AffairsMatched index dateVaccine effectivenessTarget trial emulationSARS-CoV-2-associated deathsRandomized controlled trialsCOVID-19 vaccineSARS-CoV-2-related outcomesSARS-CoV-2 testingVeterans AffairsResidual confoundingAbsence of randomized controlled trialsLong-term follow-upDocumented SARS-CoV-2 infectionTrial emulationUnvaccinated personsIndex datePositive resultsControlled trialsCOVID-19SARS-CoV-2 infectionIncomplete captureHospitalDocumented infection
2023
Effectiveness of Nirmatrelvir-Ritonavir Against the Development of Post-COVID-19 Conditions Among U.S. Veterans : A Target Trial Emulation.
Ioannou G, Berry K, Rajeevan N, Li Y, Mutalik P, Yan L, Bui D, Cunningham F, Hynes D, Rowneki M, Bohnert A, Boyko E, Iwashyna T, Maciejewski M, Osborne T, Viglianti E, Aslan M, Huang G, Bajema K. Effectiveness of Nirmatrelvir-Ritonavir Against the Development of Post-COVID-19 Conditions Among U.S. Veterans : A Target Trial Emulation. Annals Of Internal Medicine 2023, 176: 1486-1497. PMID: 37903369, PMCID: PMC10620954, DOI: 10.7326/m23-1394.Peer-Reviewed Original ResearchConceptsAcute COVID-19Veterans Health AdministrationUntreated comparatorsThromboembolic eventsCOVID-19Severe COVID-19Target trial emulationSARS-CoV-2Post COVID-19 conditionIndex dateVenous thromboembolismBaseline characteristicsCumulative incidencePulmonary embolismAcute infectionMedian ageOral antiviralsTrial emulationVHA careOutpatient treatmentInternational ClassificationHealth AdministrationU.S. veteransVeterans AffairsOrgan systems
2022
Association of Kidney Comorbidities and Acute Kidney Failure With Unfavorable Outcomes After COVID-19 in Individuals With the Sickle Cell Trait
Verma A, Huffman JE, Gao L, Minnier J, Wu WC, Cho K, Ho YL, Gorman BR, Pyarajan S, Rajeevan N, Garcon H, Joseph J, McGeary JE, Suzuki A, Reaven PD, Wan ES, Lynch JA, Petersen JM, Meigs JB, Freiberg MS, Gatsby E, Lynch KE, Zekavat SM, Natarajan P, Dalal S, Jhala DN, Arjomandi M, Bonomo RA, Thompson TK, Pathak GA, Zhou JJ, Donskey CJ, Madduri RK, Wells QS, Gelernter J, Huang RDL, Polimanti R, Chang KM, Liao KP, Tsao PS, Sun YV, Wilson PWF, O’Donnell C, Hung AM, Gaziano JM, Hauger RL, Iyengar SK, Luoh SW, Muralidhar S, Beckham J, Moser J, Thomann L, Garcon H, Kosik N, Damrauer S, Assimes T, Roussos P, Striker R, Tuteja S, DuVall S, Lynch K, Gatsby E, Ramoni R, Breeling J, Huang G, Whitbourne S, Brewer J, Aslan M, Connor T, Argyres D, Stephens B, Brophy M, Humphries D, Selva L, Do N, Shayan S, Churby L, Hauser E, Zhao H, Wilson P, McArdle R, Dellitalia L, Mattocks K, Harley J, Whittle J, Jacono F, Wells J, Gutierrez S, Gibson G, Hammer K, Kaminsky L, Villareal G, Kinlay S, Xu J, Hamner M, Mathew R, Bhushan S, Iruvanti P, Godschalk M, Ballas Z, Ivins D, Mastorides S, Moorman J, Gappy S, Klein J, Ratcliffe N, Florez H, Okusaga O, Murdoch M, Sriram P, Yeh S, Tandon N, Jhala D, Aguayo S, Cohen D, Sharma S, Liangpunsakul S, Oursler K, Whooley M, Ahuja S, Constans J, Meyer P, Greco J, Rauchman M, Servatius R, Gaddy M, Wallbom A, Morgan T, Stapley T, Sherman S, Ross G, Tsao P, Strollo P, Boyko E, Meyer L, Gupta S, Huq M, Fayad J, Hung A, Lichy J, Hurley R, Robey B. Association of Kidney Comorbidities and Acute Kidney Failure With Unfavorable Outcomes After COVID-19 in Individuals With the Sickle Cell Trait. JAMA Internal Medicine 2022, 182: 796-804. PMID: 35759254, PMCID: PMC9237798, DOI: 10.1001/jamainternmed.2022.2141.Peer-Reviewed Original ResearchConceptsAcute kidney failureSickle cell traitAssociation of SCTCOVID-19 outcomesCOVID-19 mortalityKidney diseaseKidney failureCell traitMillion Veteran ProgramCOVID-19Chronic kidney diseaseDiabetic kidney diseaseHypertensive kidney diseaseElectronic health recordsIndex dateAfrican ancestryPulmonary embolismClinical outcomesCerebrovascular diseaseMean ageUnfavorable outcomeClinical dataDiseases codesKidney morbidityMAIN OUTCOME
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply